The trajectory of the erectile dysfunction drug presents a complex picture for investors. While the initial release generated substantial returns, the lapse of its patent opened the avenue to cheaper versions, dramatically eroding market share. This creates a particular risk for firms relying on related blockbuster offerings, suggesting that a blin

The story of Viagra, and its developer copyright, presents a challenging case study for investors. Initially a blockbuster drug, yielding billions in sales , its patent expiration created a deluge of knock-off medications, significantly eroding its dominance. While some pharmaceutical companies may seek to capitalize on male sexual dysfunction, the